克罗恩病内镜下病变位置而非严重程度影响内镜缓解率:TAILORIX事后分析
该研究为TAILORIX随机对照试验的事后分析,纳入122例接受英夫利西单抗联合治疗的生物制剂初治活动性克罗恩病患者,于第0、12、54周行回结肠镜检查。结果显示基线内镜溃疡严重程度不影响愈合率,但回肠段缓解率低于结肠段。
要点
- 基线溃疡严重程度(深溃疡 vs 浅溃疡)不影响第12周和54周的内镜愈合率。
- 回肠段的内镜缓解率在第12周和54周均显著低于结肠段。
- 直肠段的内镜缓解率也低于结肠段。
核心结论
- 在生物制剂初治的克罗恩病患者中,基线内镜病变的严重程度不影响内镜愈合率,但回肠病变的内镜缓解率低于结肠。
研究设计与样本
- TAILORIX随机对照试验的事后分析,纳入122例接受英夫利西单抗联合治疗的生物制剂初治活动性克罗恩病患者,共379个病变肠段。
- 于第0、12、54周行回结肠镜检查,由盲法读者对回结肠各段分别评分。
主要发现
- 第0、12、54周的中位CDEIS评分分别为9.9(IQR 6.1-14.4)、2.4(IQR 0.2-4.6)、0.2(IQR 0.0-3.7)。
- 第12周和第54周的内镜愈合率分别为41%和61%,完全内镜缓解率分别为61%和73%。
- 基线深溃疡患者与仅有浅溃疡患者在第12周和54周的中位CDEIS评分相似。
- 回肠段缓解率在第12周和54周均低于结肠段(所有比较P < 0.01),直肠段也低于结肠段(P = 0.02和P = 0.03)。
关键数值与推荐
- 内镜愈合定义为无溃疡,完全内镜缓解定义为CDEIS < 3。
临床怎么用
- 评估克罗恩病内镜缓解时需关注病变位置,回肠和直肠病变的缓解率可能低于结肠。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The impact of severity and location of Crohn's disease (CD) endoscopic ulcers on endoscopic remission in patients treated with antitumor necrosis factor is poorly known. We aimed to describe the endoscopic evolution of CD lesions in a prospective cohort of patients treated with infliximab (IFX) in combo therapy. METHODS: We conducted a post hoc analysis of the TAILORIX randomized controlled trial, which studied biologic-naïve patients with active CD and endoscopic ulcers receiving IFX combo therapy. Ileocolonoscopies were performed at week 0, 12, and 54. Endoscopic healing was defined as the absence of ulcers and complete endoscopic remission as CD Endoscopic Index of Severity (CDEIS) <3. Ileocolonic segments were scored separately for remission by blinded readers. RESULTS: A total of 122 (median disease duration: 7 months) patients were included, corresponding with 379 diseased segments. The median (IQR) CDEIS scores at week 0, 12, and 54 were 9.9 (6.1-14.4), 2.4 (0.2-4.6), and 0.2 (0.0-3.7), respectively. At weeks 12 and 54, the rates of endoscopic healing and complete endoscopic remission were 41% and 61% and 61% and 73%, respectively. Median CDEIS scores were similar among patients with deep ulcers at baseline and those with only superficial ulcers at week 12 and 54. Segmental remission rates were lower both at week 12 and 54 in the ileum compared with colonic segments (P < 0.01 all comparisons) and in the rectum (P = 0.02 and P = 0.03). DISCUSSION: In biologic-naive patients with CD treated with IFX combo therapy, the severity of endoscopic lesions at the baseline did not influence healing rates. Endoscopic remission occurs less frequently in the ileum compared with the colon.
引用
- Rivière P, D'Haens G, Peyrin-Biroulet L, et al. Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX. Am J Gastroenterol. 2021. PMID: 33177349. doi:10.14309/ajg.0000000000000834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。